Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.
Also called NCT03449199
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 130 participants
- Sponsor
- Teijin America, Inc.
- Registry
-
NCT03449199
-
- Other papers using this trial's data
- A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03449199. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-10 (actual); primary completion 2019-05-07 (actual). Results posted on 2022-08-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- TMX-049
- Intervention (Drug)
- Placebo
- Lead sponsor
- Teijin America, Inc.
Record details
- Record id
cardio:ct-nct03449199- Content hash
a585660d577360f739d2b16aed485bd69150089f9f65bb10b9f59a9cd1e0b459